Angiotensin (Ang) II plays a critical role in cardiovascular remodeling. Krüppel-like factor (KLF) 5 is a novel indicated mediator in Ang II-induced cardiovascular damage. However, the potential link between KLF5 and Ang II has not been well investigated. In this study, we showed that in growth-arrested vascular smooth muscle cells (VSMCs), Ang II induced cell proliferation, KLF5 mRNA and protein expression in a dose-and time-dependent fashion, whereas KLF5 mRNA stability was not affected. The AT 1 antagonist losartan significantly blocked Ang II-induced KLF5 expression. Furthermore, several intracellular signals elicited by Ang II were involved in KLF5 gene upregulation, including phosphate tyrosine kinase, mitogen-activated protein kinases and reactive oxygen species. These data, for the first time, revealed the involvements of some intracellular signals in the regulation of KLF5 expression in response to Ang II in VSMCs and showed the possible role of KLF5 in Ang II-induced cell proliferation in VSMCs.
Increasing evidence shows that Angiotensin (Ang) II plays a critical role in cardiovascular diseases and is a key mediator in the process of cardiovascular remodeling. It is well known that Ang II signals through its receptors to exert most of its biological functions. 1) After binding to the AT 1 receptor, Ang II activates multiple downstream intracellular signaling pathways, including protein kinase C (PKC), phosphate tyrosine kinase (PTK), mitogen-activated protein kinases (MAPK) and reactive oxygen species (ROS).
2) Activation of these pathways leads to numerous heterogeneous downstream events that play essential roles in the biological activities of Ang II, such as inflammation, cell growth and migration, extracellular matrix production and apoptosis. 2) Krüppel-like transcription factor (KLF) 5, also known as basic transcription element binding protein (BTEB) 2, belongs to the Krüppel-like transcription factor family. Members of this family contain three Krüppel-like C 2 H 2 -type zinc (Zn)-finger domains, recognize GC boxes, and have diverse functions in cell proliferation, differentiation, and embryonic development. [3] [4] [5] In the cardiovascular system, KLF5 is first isolated in vascular smooth muscle cells (VSMCs), and is abundantly expressed in developing blood vessels, but is downregulated in adult vessels. 6) However, its expression is strongly upregulated in activated VSMCs within the vascular lesions. [7] [8] [9] [10] In addition, in vitro studies show that in VSMCs, KLF5 induces many types of genes such as PDGF-A/-B, iNOS, PAI-1, TGF-b and VEGF receptors, which are known to be upregulated during cardiovascular remodeling. 11, 12) Moreover, in Ang II infused mice, a marked upregulation of KLF5 was observed in aorta, 13) and in KLF5
ϩ/Ϫ mice, inflammatory vascular response and Ang II-induced cardiovascular remodeling were attenuated. 9) From these studies, it can be concluded that KLF5 may be a target for Ang II signaling and an essential regulator of cardiovascular remodeling. 14, 15) Although these studies have established the emerging possible roles for KLF5 in the pathogenesis of Ang II-induced cardiovascular damage, to our knowledge, there are no studies investigating whether Ang II regulates KLF5 expression in VSMCs, and the molecular basis for inducible expression of KLF5 in response to Ang II in VSMCs remains to be determined. The present study was designed to investigate the effects of Ang II on KLF5 expression in rat VSMCs and the molecular mechanisms involved in this response.
MATERIALS AND METHODS
Reagents Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin, streptomycin and TRIzol reagent were purchased from GIBCO BRL (Carlsbad, CA, U.S.A.). Losartan was from Cayman (Cayman Co., U.S.A.). Ang II, PD123319, PD98059, SB203580, trion and actinomycin D were obtained from Sigma (St. Louis, MO, U.S.A.). Bisindolylmaleimide, phorbol 12-myristate 13-acetate (PMA), genistein and diphenyleneiodonium were from Alexis (Lausen, Switzerland). Rabbit polyclonal antibody against KLF5 (H-300, sc-22797) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.).
Cell Culture VSMCs were obtained from thoracic aorta of Sprague-Dawley rats by the collagenase method as described previously 16) and cultured in DMEM containing 10% FBS, penicillin (100 U/ml) and streptomycin (100 U/ml). VSMCs between passages 3 and 7, confirmed positive (99%) for smooth muscle a-actin immunostaining, were used in the experiments. For subsequent experiments, cells at 80% confluence in culture wells were growth-arrested by serum-starvation for 48 h.
Cell Proliferation. Cell Number Cell count experiments were performed as described previously. 17) Briefly, a suspension of VSMCs (0.5ϫ10 5 cells/ml) were prepared and treated with or without Ang II (10 Ϫ7 mol/l) for different times. Cells were counted in a hemocytometer using light microscopy.
MTT Assay Cells were grown in 96-well plates at the density of 1ϫ10 4 per well. After indicated treatments, 3-[4,5-dimethylthiozol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) at 5 mg/ml was added to each well for 4 h. The culture medium was removed. Then, 150 ml of dimethyl sulfox-ide (DMSO) was added to each well. The absorbance was measured at 490 nm using a microplate spectrophotometer (POLARstar, OPTIMA, Germany).
Real-Time RT-PCR Total cellular RNA was extracted by TRIzol reagent, according to the manufacturer's recommended protocol. In all RNA samples, DNAs were removed by using the DNA-free kit (Ambion, Austin TX, U.S.A.) according to the protocol. cDNA was synthesized from 1 mg samples of total RNA by using SuperScript TM III First Strand cDNA Synthesis Kit (Invitrogen, Carlsbad, CA, U.S.A.). Primers for rat KLF5 (forward: 5Ј-AGCCAC CAGAG CGAAT CC-3Ј; reverse: 5Ј-GCCAG CCATA GAGAC ATTAA GG-3Ј, producing a fragment of 270 bp, GenBank accession No. NM053394) and Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (forward: 5Ј-GCCTT CTCCA TGGTG GTGAA-3Ј; reverse: 5Ј-GGTCG GTGTG AACGG ATTTG-3Ј, producing a fragment of 309 bp, GenBank accession No. NM017008) were designed with Beacon designer v 4.0 (Premier Biosoft, U.S.A.). Real-time quantitative reversetranscriptase polymerase chain reaction (RT-PCR) with SYBR was performed with SYBR ® ExScript TM RT-PCR Kit (TaKaRa Bio, Japan) on an ABI PRISM 7000 sequence detection PCR system (Applied Biosystems, Foster City, CA, U.S.A.) according to the manufacturer's protocol. The PCR cycling condition was 95°C for 2 min, 40 cycles of 95°C for 10 s and 60°C for 31 s. In all experiments, control reactions were performed substituting sterile nuclease-free water for the RNA template in the reaction. The specificity of RT-PCR products was confirmed both by melting curves and visualization on 1% TAE agarose gel with ethidium bromide staining. Quantitative data of relative gene expression were determined by the comparative Ct method (2
ϪDDCt
) as described previously.
18)
Western Blot Analysis Cells were lysed with 200 ml of ice-cold lysis buffer (50 mM HEPES, 5 mM EDTA, 100 mM NaCl, 1% Triton X-100, protease inhibitors cocktails; pH 7.4) in the presence of phosphatase inhibitors (50 mM sodium fluoride, 1 mM sodium orthovanadate, 10 mM sodium pyrophosphate, 1 nM microcystin). Protein concentration was determined with the BCA protein assay kit (Pierce, Rockford, IL, U.S.A.). Protein samples (20 mg) were resolved on 10% SDS-PAGE gels and transferred onto a polyvinylidene difluoride (PVDF) membrane in semi-dry system (Bio-Rad, Hercules, CA, U.S.A.). The membranes were incubated with specific antibodies against KLF5. Immunobloting bands were revealed with chemiluminescence and visualized by exposure to X-ray films. Optical densities of bands were scanned with the Gel Doc 2000 (Bio-Rad).
Statistical Analysis Statistical significance between groups was assessed by using one-way ANOVA, followed by post hoc Duncan multiple comparisons with the SPSS 10.0 program (SPSS Inc., Chicago, IL, U.S.A.). A value of pϽ0.05 was considered to be statistically significant.
RESULTS

Ang II Induced Cell Proliferation in VSMCs
As shown in (Figs. 1A, B, C) , Ang II dose-dependently induced cell proliferation in VSMCs. Treated of cells with 10 Ϫ7 mol/l Ang II induced a significant increase in the cell proliferation in a time-dependent fashion (Figs. 1D, E) .
Ang II Induced KLF5 Expression in VSMCs
As shown by real-time RT-PCR, KLF5 mRNA was weakly expressed in growth-arrested VSMCs. Ang II stimulation rapidly increased KLF5 mRNA expression, which showed a peak at 3 h and decreased thereafter, but showed another peak at 18 h ( Fig. 2A) . As shown by western blot, Ang II also increased KLF5 protein production in VSMCs in a time-dependent fashion (Fig. 2C ). This KLF5 upregulation was dose-dependent and maximal at 10 Ϫ6 mol/l Ang II (Figs.  2B, D) .
Effect of Ang II on KLF5 mRNA Stability To examine whether the effect of Ang II on KLF5 mRNA upregulation was due to increase of KLF5 mRNA stability, we treated VSMCs with 5 mg/ml actinomycin D. As shown in (Fig. 3) , KLF5 mRNA in VSMCs untreated with Ang II (control group) degraded approximately by 50% after 8 h treatment with actinomycin D. When VSMCs pretreated with Ang II, KLF5 degradation rate was not affected. These data strongly suggested that regulation of KLF5 expression by Ang II was independent of altered KLF5 mRNA stability. It may through transcriptional level.
Ang II Increases KLF5 via AT 1 in VSMCs In VSMCs, Ang II acts through two specific receptors, AT 1 and AT 2 . We found that the AT 1 antagonist losartan caused a significant diminution in Ang II-induced KLF5 expression, whereas the AT 2 antagonist PD123319 had no effect (Fig. 4) , suggesting that Ang II-induced KLF5 upregulation was mediated through AT 1 receptors.
Molecular Mechanisms of Ang II-Induced KLF5 Gene Production Ang II, via AT 1 , activated several intracellular mediators, including PKC, PTK, MAPK and production of intracellular ROS. In accordance with previous study, 19) we found PKC activator PMA increased KLF5 expression in VSMCs. Moreover we showed that PKC inhibitor bisindolylmaleimide reduced the stimulatory effect of Ang II on KLF5 mRNA expression. PTK inhibitor genistein showed no effect on Ang II-induced KLF5 gene expression. Treatment of VSMCs with the Erk P42/44 inhibitor PD98059 markedly diminished Ang II-induced KLF5 mRNA expression, whereas the P38 inhibitor SB203580 had no effect (Fig. 5A ). In VSMCs, exogenous H 2 O 2 increased KLF5 mRNA expression. The NADH/NADPH oxidase inhibitor diphenyleneiodonium and the O 2Ϫ scavenger trion markedly diminished Ang II-induced KLF5 mRNA expression (Fig. 5B) .
These data suggested that Ang II, via AT 1 , through the activation of several protein kinases and by a redoxsensitive mechanism, regulated KLF5 gene expression.
DISCUSSION
In this study, we demonstrate that Ang II is capable of inducing cell proliferation and KLF5 expression in VSMCs, as previously shown in cultured cardiac fibroblast, 9) and that Ang II do not affect KLF5 mRNA stability, suggesting KLF5 mRNA upregulation may be mediated at the gene transcriptional level. More importantly, our results show that this effect of Ang II on KLF5 expression is mediated mainly through AT 1 R in the VSMCs, and followed by PKC, MAPK and ROS activation. This study further represents the possible link between Ang II and KLF5.
It was demonstrated that systemic infusion of Ang II into mice, caused a marked aortic KLF5 induction and vascular remodeling, 13) and in KLF5 ϩ/Ϫ mice, Ang II-induced cardiovascular remodeling was reduced.
9) Furthermore, it is believed that the amount of KLF5 expression may be important for development of cardiovascular remodeling because attenuated cellular responses in KLF5 ϩ/Ϫ mice were associated with reduced expression of KLF5. 15) In this report, we set out to determine the effects of Ang II stimulation on KLF5 expression in VSMCs in vitro. VSMCs grown in the presence of Ang II showed a dose-and time-dependent increase in KLF5 mRNA expression and unchanged mRNA stability, which indicated that Ang II caused a direct, non-pressuremediated KLF5 upregulation. This mechanism may be involved in vascular remodeling caused by Ang II.
It is well known that Ang II is a potential trigger of cell proliferation in VSMCs and previous studies have documented KLF5 as an yang regulator in cell proliferation.
20) It is demonstrated that the level of KLF5 mRNA is low in serum-deprived, quiescent NIH3T3 cells, but is acutely and significantly increased upon addition of serum or phorbol ester. 21) Furthermore, constitutive expression of KLF5 results in an increased rate of proliferation in many types of cells. 22) In this study, we found that Ang II induced cell proliferation in a dose-and time-dependent fashion, and more importantly, these changes were accompanied with KLF5 upregulation, which revealed the possible role of KLF5 in Ang II-induced cell proliferation in VSMCs.
Ang II acts through its binding to specific receptors. 1) AT 1 is responsible for most of the pathophysiological actions of Ang II. It contributes to chronic diseases, such as hypertension, atherosclerosis and cardiac hypertrophy, by promoting cell growth, inflammation and fibrosis. 1, 23, 24) AT 2 is involved in cell growth inhibition and inflammatory cell recruitment. 1, 23) We have observed that in cultured VSMCs, AT 1 antagonist losartan diminished KLF5 mRNA and protein expression in response to Ang II, whereas AT 2 antagonist PD123319 had no effect. Our data clearly demonstrate that Ang II via AT 1 regulates KLF5 expression.
The molecular mechanisms linked to AT 1 activation are common to classic cytokines and include activation of several kinases. 1) Among the intracellular signaling systems involved in Ang II-induced proliferation, hypertrophy and matrix regulation, PKC, PTK and MAPK activation play an important role in different cell types.
2) Our data demonstrate that in VSMCs, Ang II regulates KLF5 expression via AT 1 and activation of PKC, whereas PTK activation makes a minimal contribution. Coincident result has been described. 19) Through Erk P42/44 but not P38 MAPK, PKC activator PMA increased KLF5 gene and production. Our results demonstrate that Ang II induces KLF5 expression via AT 1 receptor and activation of PKC and Erk P42/44, whereas P38 MAPK makes little contribution. Ang II, via AT 1 , increased H 2 O 2 generation through phospholipase D-dependent and NADH/NADPH oxidase-sensitive pathways.
1) Diverse antioxidants blocked KLF5 production elicited by Ang II, suggesting that ROS act as intermediates of AT 1 -mediated KLF5 production. ROS also mediate other Ang II effects, including cell proliferation, protein synthesis and intracellular responses, such as activation of MAPK, nuclear factor-kB, and activator protein-1. 1, 25) Altogether, these data suggest that Ang II, via AT 1 , elicit several intracellular signals, such as PKC, Erk P42/44 activation and ROS production, which contribute to KLF5 regulation.
In conclusion, the results from the present study indicate that Ang II induces KLF5 expression in VSMCs. More importantly we demonstrate that Ang II regulates KLF5 expres- sion via AT 1 receptor and activation of PKC and Erk P42/44 or ROS production. These data may contribute to our knowledge of the mechanisms underlying Ang II-induced cardiovascular damage.
